Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04819841
PHASE1/PHASE2

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Sponsor: Kamau Therapeutics

View on ClinicalTrials.gov

Summary

This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.

Official title: A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease

Key Details

Gender

All

Age Range

12 Years - 40 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2021-11-15

Completion Date

2028-12-31

Last Updated

2026-03-11

Healthy Volunteers

No

Interventions

GENETIC

nula-cel Drug Product

nula-cel is administered via IV infusion following a myeloablative conditioning regimen

Locations (4)

Children's Hospital Los Angeles

Los Angeles, California, United States

Lucile Packard Children's Hospital

Palo Alto, California, United States

Washington University

St Louis, Missouri, United States

Nationwide Children's Hospital

Columbus, Ohio, United States